Lisa Pham

(Bloomberg) -- Amid the stock market frenzy surrounding weight-loss medicines, one Belgian biotech company is rewarding investors by focusing on a much more low-profile area of drug development: Treatments for skin disease. Most Read from BloombergUrban Heat Stress Is Another Disparity in the World’s Most Unequal NationSingapore Ends 181 Years of Horse Racing to Make Way for HomesFrom Cleveland to Chicago, NFL Teams Dream of Domed StadiumsWhat Do US Vehicle Regulators Have Against Tiny Cars?For

(Bloomberg) -- During what’s been a tough year for European airline stocks, one UK carrier is bucking the gloom.Most Read from BloombergHow Mexico City Averted All-Out DroughtDubai’s Allure to Expats Is Weighing on City’s InfrastructureThe Master Plan That Shaped Pakistan’s Capital Is No Longer WorkingAs Brussels Booms, an Old Boogeyman Returns: BrusselizationThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsJet2 Plc shares have risen 15% this year, with the stock extending ga

Larson & Gaston, LLP, a law firm dedicated to serving businesses in California, addressed the use of PAGA reform to help businesses reduce penalties.

Hi, it’s Lisa in London, where I’ve recently been able to smell coffee again for the first time in a while. But before we get to that...

Hi, it’s Lisa in London. As the world debates how to curb the spread of superbugs, researchers in the US are experimenting with the idea that electric currents could decrease skin infections. But before we get to that...

(Bloomberg) -- AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it had slumped to little more than £150 billion and the drugmaker had lost its spot as the UK’s biggest company by market value to Shell Plc.Most Read from BloombergKey Ballot Initiatives and Local Races Highlight Views on Abortion, ImmigrationParis Restricts Through Traffic in City CenterFrom Housing to Immigration, Key Ballot Initiatives and Local Races to Foll

(Bloomberg) -- AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it had slumped to little more than £150 billion and the drugmaker had lost its spot as the UK's biggest company by market value to Shell Plc.

This week's selloff in renewable energy stocks following Donald Trump 's election victory has been a boon for short sellers betting against clean energy.

(Bloomberg) — This week's selloff in renewable energy stocks following Donald Trump's election victory has been a boon for short sellers betting against clean energy.

Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, after analysts at JPMorgan Chase & Co. predicted the Danish biotech firm’s experimental weight-loss drug petrelintide could generate $10 billion in peak sales.